Ontology type: schema:ScholarlyArticle
2017-09-25
AUTHORSStefan Müller-Hülsbeck, Koen Keirse, Thomas Zeller, Herman Schroë, Juan Diaz-Cartelle
ABSTRACTPurpose To report the 3-year results of the MAJESTIC first-in-human study of the Eluvia Drug-Eluting Vascular Stent System for treating femoropopliteal artery lesions.MethodsThe prospective, single-arm, multicenter clinical trial enrolled 57 patients with symptomatic lower limb ischemia (Rutherford category 2, 3, or 4) and lesions in the superficial femoral artery or proximal popliteal artery. Mean lesion length was 70.8 ± 28.1 mm, and 46% of lesions were occluded. Efficacy measures at 2 years included primary patency, defined as duplex ultrasound peak systolic velocity ratio of ≤2.5 and the absence of target lesion revascularization (TLR) or bypass. Safety monitoring through 3 years included adverse events and TLR.ResultsPrimary patency was estimated as 83.5% (Kaplan–Meier analysis) at 24 months, and 90.6% (48/53) of patients maintained an improvement in Rutherford class. At 36 months, the Kaplan–Meier estimate of freedom from TLR was 85.3%. No stent fractures were identified, and no major target limb amputations occurred.ConclusionMAJESTIC results demonstrated long-term treatment durability among patients whose femoropopliteal arteries were treated with the paclitaxel-eluting Eluvia stent.Level of EvidenceLevel 2b, cohort study More... »
PAGES1832-1838
http://scigraph.springernature.com/pub.10.1007/s00270-017-1771-5
DOIhttp://dx.doi.org/10.1007/s00270-017-1771-5
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1091920032
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/28948322
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1199",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Other Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents, Phytogenic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease-Free Survival",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug-Eluting Stents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Femoral Artery",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Follow-Up Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Kaplan-Meier Estimate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Paclitaxel",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Peripheral Arterial Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Popliteal Artery",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ultrasonography, Doppler, Duplex",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Vascular Patency",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Diagnostic and Interventional Radiology/Neuroradiology, Ev. Luth. Diakonissenanstalt Flensburg, Knuthstr. 1, 24939, Flensburg, Germany",
"id": "http://www.grid.ac/institutes/grid.477194.8",
"name": [
"Department of Diagnostic and Interventional Radiology/Neuroradiology, Ev. Luth. Diakonissenanstalt Flensburg, Knuthstr. 1, 24939, Flensburg, Germany"
],
"type": "Organization"
},
"familyName": "M\u00fcller-H\u00fclsbeck",
"givenName": "Stefan",
"id": "sg:person.0775352560.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775352560.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Regional Hospital Heilig Hart Tienen, Tienen, Belgium",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Regional Hospital Heilig Hart Tienen, Tienen, Belgium"
],
"type": "Organization"
},
"familyName": "Keirse",
"givenName": "Koen",
"id": "sg:person.0656407074.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656407074.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Germany",
"id": "http://www.grid.ac/institutes/grid.418466.9",
"name": [
"Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Germany"
],
"type": "Organization"
},
"familyName": "Zeller",
"givenName": "Thomas",
"id": "sg:person.01306206724.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306206724.74"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ziekenhuis Oost-Limburg, Genk, Belgium",
"id": "http://www.grid.ac/institutes/grid.470040.7",
"name": [
"Ziekenhuis Oost-Limburg, Genk, Belgium"
],
"type": "Organization"
},
"familyName": "Schro\u00eb",
"givenName": "Herman",
"id": "sg:person.0767170333.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767170333.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Boston Scientific Corporation, Marlborough, MA, USA",
"id": "http://www.grid.ac/institutes/grid.418905.1",
"name": [
"Boston Scientific Corporation, Marlborough, MA, USA"
],
"type": "Organization"
},
"familyName": "Diaz-Cartelle",
"givenName": "Juan",
"id": "sg:person.01353763750.59",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353763750.59"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00270-009-9601-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041508668",
"https://doi.org/10.1007/s00270-009-9601-z"
],
"type": "CreativeWork"
}
],
"datePublished": "2017-09-25",
"datePublishedReg": "2017-09-25",
"description": "Purpose\nTo report the 3-year results of the MAJESTIC first-in-human study of the Eluvia Drug-Eluting Vascular Stent System for treating femoropopliteal artery lesions.MethodsThe prospective, single-arm, multicenter clinical trial enrolled 57 patients with symptomatic lower limb ischemia (Rutherford category 2, 3, or 4) and lesions in the superficial femoral artery or proximal popliteal artery. Mean lesion length was 70.8\u00a0\u00b1\u00a028.1\u00a0mm, and 46% of lesions were occluded. Efficacy measures at 2\u00a0years included primary patency, defined as duplex ultrasound peak systolic velocity ratio of \u22642.5 and the absence of target lesion revascularization (TLR) or bypass. Safety monitoring through 3\u00a0years included adverse events and TLR.ResultsPrimary patency was estimated as 83.5% (Kaplan\u2013Meier analysis) at 24\u00a0months, and 90.6% (48/53) of patients maintained an improvement in Rutherford class. At 36\u00a0months, the Kaplan\u2013Meier estimate of freedom from TLR was 85.3%. No stent fractures were identified, and no major target limb amputations occurred.ConclusionMAJESTIC results demonstrated long-term treatment durability among patients whose femoropopliteal arteries were treated with the paclitaxel-eluting Eluvia stent.Level of EvidenceLevel 2b, cohort study",
"genre": "article",
"id": "sg:pub.10.1007/s00270-017-1771-5",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1091062",
"issn": [
"0174-1551",
"1432-086X"
],
"name": "CardioVascular and Interventional Radiology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "12",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "40"
}
],
"keywords": [
"target lesion revascularization",
"symptomatic lower limb ischemia",
"major target limb amputation",
"long-term treatment durability",
"femoropopliteal artery lesions",
"proximal popliteal artery",
"peak systolic velocity ratio",
"target limb amputation",
"lower limb ischemia",
"superficial femoral artery",
"Kaplan-Meier estimates",
"long-term results",
"multicenter clinical trial",
"systolic velocity ratio",
"Rutherford class",
"primary patency",
"lesion revascularization",
"artery lesions",
"limb ischemia",
"adverse events",
"popliteal artery",
"efficacy measures",
"femoropopliteal arteries",
"femoral artery",
"clinical trials",
"stent fracture",
"limb amputation",
"human studies",
"stent system",
"treatment durability",
"patients",
"artery",
"lesion length",
"lesions",
"patency",
"trials",
"months",
"revascularization",
"ischemia",
"bypass",
"amputation",
"cohort",
"years",
"stents",
"paclitaxel",
"drugs",
"MethodsThe",
"treatment",
"safety",
"fractures",
"absence",
"levels",
"velocity ratio",
"study",
"results",
"measures",
"events",
"improvement",
"purpose",
"ratio",
"length",
"estimates",
"eluvium",
"system",
"class",
"durability",
"freedom",
"Majestic"
],
"name": "Long-Term Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Femoropopliteal Treatment: 3-Year Follow-up",
"pagination": "1832-1838",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1091920032"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00270-017-1771-5"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"28948322"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00270-017-1771-5",
"https://app.dimensions.ai/details/publication/pub.1091920032"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:17",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_755.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00270-017-1771-5"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00270-017-1771-5'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00270-017-1771-5'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00270-017-1771-5'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00270-017-1771-5'
This table displays all metadata directly associated to this object as RDF triples.
242 TRIPLES
22 PREDICATES
112 URIs
103 LITERALS
24 BLANK NODES